The impact of MK-467 on sedation, heart rate and arterial blood pressure after intramuscular coadministration with dexmedetomidine in conscious cats

Juhana Honkavaara, Bruno H Pypendop, Jan Ilkiw

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective To study the effects of MK-467, a peripheral α2-adrenoceptor antagonist, on sedation, heart rate and blood pressure after intramuscular (IM) coadministration with 25 μg kg−1 of dexmedetomidine in cats. Study design Prospective, randomized, controlled, blinded, cross-over, experimental study. Animals A total of eight healthy, adult, neutered male cats. Methods Cats were administered five IM treatments at least 2 weeks apart, consisting of dexmedetomidine 25 μg kg−1 (D25), MK-467 600 μg kg−1 (M600) and D25 combined with 300, 600 and 1200 μg kg−1 of MK-467 (D25M300, D25M600 and D25M1200, respectively). Heart rate and direct arterial blood pressure were recorded via telemetry and sedation assessed prior to treatments and at intervals for 8 hours thereafter. Results Heart rate decreased significantly after all treatments with dexmedetomidine and remained below baseline up to 240 (D25), 20 (D25M300) and 3 minutes (D25M600 and D25M1200). Mean arterial pressure (MAP) increased with D25, remained unchanged with M600 and decreased over time with all combination treatments. The highest and lowest MAP after each treatment were 168 ± 17 and 100 ± 14 (D25), 157 ± 18 and 79 ± 11 (D25M300), 153 ± 11 and 74 ± 10 (D25M600), 144 ± 12 and 69 ± 7 (D25M1200) and 136 ± 9 and 104 ± 13 mmHg (M600). All treatments with dexmedetomidine produced sedation although its duration was significantly reduced by the addition of MK-467. Conclusions and clinical relevance Dexmedetomidine induced bradycardia and hypertension, which were attenuated by all three doses of MK-467. The duration of sedation was reduced by MK-467. MK-467 may improve the cardiovascular tolerance of IM dexmedetomidine in cats.

Original languageEnglish (US)
Pages (from-to)811-822
Number of pages12
JournalVeterinary Anaesthesia and Analgesia
Volume44
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

L 659066
dexmedetomidine
Dexmedetomidine
sedation
blood pressure
heart rate
Arterial Pressure
Cats
Heart Rate
cats
duration
adrenergic receptors
Telemetry
telemetry
hypertension
Bradycardia
antagonists
Cross-Over Studies
Adrenergic Receptors
experimental design

Keywords

  • cat
  • dexmedetomidine
  • heart rate
  • intramuscular
  • MK-467

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{7d8b95b9354842ce976807525138d445,
title = "The impact of MK-467 on sedation, heart rate and arterial blood pressure after intramuscular coadministration with dexmedetomidine in conscious cats",
abstract = "Objective To study the effects of MK-467, a peripheral α2-adrenoceptor antagonist, on sedation, heart rate and blood pressure after intramuscular (IM) coadministration with 25 μg kg−1 of dexmedetomidine in cats. Study design Prospective, randomized, controlled, blinded, cross-over, experimental study. Animals A total of eight healthy, adult, neutered male cats. Methods Cats were administered five IM treatments at least 2 weeks apart, consisting of dexmedetomidine 25 μg kg−1 (D25), MK-467 600 μg kg−1 (M600) and D25 combined with 300, 600 and 1200 μg kg−1 of MK-467 (D25M300, D25M600 and D25M1200, respectively). Heart rate and direct arterial blood pressure were recorded via telemetry and sedation assessed prior to treatments and at intervals for 8 hours thereafter. Results Heart rate decreased significantly after all treatments with dexmedetomidine and remained below baseline up to 240 (D25), 20 (D25M300) and 3 minutes (D25M600 and D25M1200). Mean arterial pressure (MAP) increased with D25, remained unchanged with M600 and decreased over time with all combination treatments. The highest and lowest MAP after each treatment were 168 ± 17 and 100 ± 14 (D25), 157 ± 18 and 79 ± 11 (D25M300), 153 ± 11 and 74 ± 10 (D25M600), 144 ± 12 and 69 ± 7 (D25M1200) and 136 ± 9 and 104 ± 13 mmHg (M600). All treatments with dexmedetomidine produced sedation although its duration was significantly reduced by the addition of MK-467. Conclusions and clinical relevance Dexmedetomidine induced bradycardia and hypertension, which were attenuated by all three doses of MK-467. The duration of sedation was reduced by MK-467. MK-467 may improve the cardiovascular tolerance of IM dexmedetomidine in cats.",
keywords = "cat, dexmedetomidine, heart rate, intramuscular, MK-467",
author = "Juhana Honkavaara and Pypendop, {Bruno H} and Jan Ilkiw",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.vaa.2016.08.011",
language = "English (US)",
volume = "44",
pages = "811--822",
journal = "Veterinary Anaesthesia and Analgesia",
issn = "1467-2987",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The impact of MK-467 on sedation, heart rate and arterial blood pressure after intramuscular coadministration with dexmedetomidine in conscious cats

AU - Honkavaara, Juhana

AU - Pypendop, Bruno H

AU - Ilkiw, Jan

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective To study the effects of MK-467, a peripheral α2-adrenoceptor antagonist, on sedation, heart rate and blood pressure after intramuscular (IM) coadministration with 25 μg kg−1 of dexmedetomidine in cats. Study design Prospective, randomized, controlled, blinded, cross-over, experimental study. Animals A total of eight healthy, adult, neutered male cats. Methods Cats were administered five IM treatments at least 2 weeks apart, consisting of dexmedetomidine 25 μg kg−1 (D25), MK-467 600 μg kg−1 (M600) and D25 combined with 300, 600 and 1200 μg kg−1 of MK-467 (D25M300, D25M600 and D25M1200, respectively). Heart rate and direct arterial blood pressure were recorded via telemetry and sedation assessed prior to treatments and at intervals for 8 hours thereafter. Results Heart rate decreased significantly after all treatments with dexmedetomidine and remained below baseline up to 240 (D25), 20 (D25M300) and 3 minutes (D25M600 and D25M1200). Mean arterial pressure (MAP) increased with D25, remained unchanged with M600 and decreased over time with all combination treatments. The highest and lowest MAP after each treatment were 168 ± 17 and 100 ± 14 (D25), 157 ± 18 and 79 ± 11 (D25M300), 153 ± 11 and 74 ± 10 (D25M600), 144 ± 12 and 69 ± 7 (D25M1200) and 136 ± 9 and 104 ± 13 mmHg (M600). All treatments with dexmedetomidine produced sedation although its duration was significantly reduced by the addition of MK-467. Conclusions and clinical relevance Dexmedetomidine induced bradycardia and hypertension, which were attenuated by all three doses of MK-467. The duration of sedation was reduced by MK-467. MK-467 may improve the cardiovascular tolerance of IM dexmedetomidine in cats.

AB - Objective To study the effects of MK-467, a peripheral α2-adrenoceptor antagonist, on sedation, heart rate and blood pressure after intramuscular (IM) coadministration with 25 μg kg−1 of dexmedetomidine in cats. Study design Prospective, randomized, controlled, blinded, cross-over, experimental study. Animals A total of eight healthy, adult, neutered male cats. Methods Cats were administered five IM treatments at least 2 weeks apart, consisting of dexmedetomidine 25 μg kg−1 (D25), MK-467 600 μg kg−1 (M600) and D25 combined with 300, 600 and 1200 μg kg−1 of MK-467 (D25M300, D25M600 and D25M1200, respectively). Heart rate and direct arterial blood pressure were recorded via telemetry and sedation assessed prior to treatments and at intervals for 8 hours thereafter. Results Heart rate decreased significantly after all treatments with dexmedetomidine and remained below baseline up to 240 (D25), 20 (D25M300) and 3 minutes (D25M600 and D25M1200). Mean arterial pressure (MAP) increased with D25, remained unchanged with M600 and decreased over time with all combination treatments. The highest and lowest MAP after each treatment were 168 ± 17 and 100 ± 14 (D25), 157 ± 18 and 79 ± 11 (D25M300), 153 ± 11 and 74 ± 10 (D25M600), 144 ± 12 and 69 ± 7 (D25M1200) and 136 ± 9 and 104 ± 13 mmHg (M600). All treatments with dexmedetomidine produced sedation although its duration was significantly reduced by the addition of MK-467. Conclusions and clinical relevance Dexmedetomidine induced bradycardia and hypertension, which were attenuated by all three doses of MK-467. The duration of sedation was reduced by MK-467. MK-467 may improve the cardiovascular tolerance of IM dexmedetomidine in cats.

KW - cat

KW - dexmedetomidine

KW - heart rate

KW - intramuscular

KW - MK-467

UR - http://www.scopus.com/inward/record.url?scp=85031090523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031090523&partnerID=8YFLogxK

U2 - 10.1016/j.vaa.2016.08.011

DO - 10.1016/j.vaa.2016.08.011

M3 - Article

C2 - 28734853

AN - SCOPUS:85031090523

VL - 44

SP - 811

EP - 822

JO - Veterinary Anaesthesia and Analgesia

JF - Veterinary Anaesthesia and Analgesia

SN - 1467-2987

IS - 4

ER -